StockNews.AI
SLNO
StockNews.AI
5 hrs

SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigates Soleno for potential securities law violations. 2. Scorpion Capital reported Vykat XR as overpriced and potentially unsafe for children. 3. SLNO stock fell 7.41% following the negative report from Scorpion Capital. 4. Investors with losses are encouraged to discuss legal options without obligation. 5. Legal scrutiny may impact investor sentiment and stock price for SLNO.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation into Soleno raises concerns over business practices and may suggest deeper issues, similar to how previous firm investigations have led to long-lasting stock declines in similar companies. Such legal actions often intimidate investors leading to reduced confidence and potential divestment.

How important is it?

Legal investigations directly relate to investor confidence and can sharply influence stock performance. The emphasis on contacting a law firm indicates a significant level of concern among stakeholders.

Why Short Term?

Immediate effects are likely due to investor uncertainty, as seen historically when firms face similar legal challenges. However, the long-term impact may depend on the outcome of the investigation and response by Soleno.

Related Companies

SLNO
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) on behalf of Soleno stockholders. Our investigation concerns whether Soleno has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children.Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. Next Steps: If you purchased or otherwise acquired Soleno shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News